000283145 001__ 283145
000283145 005__ 20260108145930.0
000283145 0247_ $$2doi$$a10.1002/alz70856_104796
000283145 0247_ $$2ISSN$$a1552-5260
000283145 0247_ $$2ISSN$$a1552-5279
000283145 037__ $$aDZNE-2026-00041
000283145 041__ $$aEnglish
000283145 082__ $$a610
000283145 1001_ $$aBathe, Tim$$b0
000283145 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283145 245__ $$aMulti‐tracer PET monitoring of an immunomodulatory therapy in 4R tauopathy: Evaluating a novel drug's impact on glial function and protein pathology
000283145 260__ $$c2025
000283145 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767880750_14468
000283145 3367_ $$033$$2EndNote$$aConference Paper
000283145 3367_ $$2BibTeX$$aINPROCEEDINGS
000283145 3367_ $$2DRIVER$$aconferenceObject
000283145 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283145 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283145 3367_ $$2ORCID$$aOTHER
000283145 520__ $$aThe prevalence of neurodegenerative diseases (ND), including Alzheimer's disease (AD) and non-AD tauopathies, is projected to rise significantly by 2050 due to an aging global population. Chronic neuroinflammation, driven by glial activation in response to protein pathologies, is a major contributor to disease progression. Targeting glial dysfunction through immunomodulatory therapies offers a promising approach to mitigate the effects of tauopathies and other ND.PS19 mice receive chronic treatment with GV1001 over 5 months. Serial neuroimaging techniques, including PET scans targeting tau protein, microglial activation, and astrocytic responses, are employed to assess treatment effects in vivo (Figure 1). Postmortem validation is performed using immunohistochemistry and biochemical methods, comparing treated mice to placebo and non-transgenic controls.The research scope is to monitor the efficacy of GV1001 in a transgenic tau mouse model (PS19) with an early-intervention biomarker study using molecular biology and neuroimaging techniques including TSPO (microglia) PET, deprenyl (astroglia) PET, tau PET (perfusion and retention) and CSF markers of inflammation (e.g. sTREM2) and neurodegeneration (NfL). Preliminary findings, expected to be presented at the conference, will provide insights into the drug's ability to modulate glial activity, restore homeostasis, and reduce tau pathology.This study highlights the potential of monitoring immunomodulatory strategies to address the complex interplay between chronic neuroinflammation and protein aggregation in ND. If successful, these findings could inform the development of novel therapeutic approaches for AD and related disorders, bridging the gap between preclinical research and clinical application.
000283145 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000283145 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283145 650_7 $$2NLM Chemicals$$aBiomarkers
000283145 650_7 $$2NLM Chemicals$$atau Proteins
000283145 650_2 $$2MeSH$$aAnimals
000283145 650_2 $$2MeSH$$aBiomarkers: cerebrospinal fluid
000283145 650_2 $$2MeSH$$aBiomarkers: metabolism
000283145 650_2 $$2MeSH$$aMice
000283145 650_2 $$2MeSH$$aMice, Transgenic
000283145 650_2 $$2MeSH$$aDisease Models, Animal
000283145 650_2 $$2MeSH$$aAlzheimer Disease: drug therapy
000283145 650_2 $$2MeSH$$aPositron-Emission Tomography
000283145 650_2 $$2MeSH$$atau Proteins: metabolism
000283145 650_2 $$2MeSH$$aHumans
000283145 650_2 $$2MeSH$$aBrain: metabolism
000283145 650_2 $$2MeSH$$aBrain: pathology
000283145 650_2 $$2MeSH$$aBrain: diagnostic imaging
000283145 650_2 $$2MeSH$$aBrain: drug effects
000283145 650_2 $$2MeSH$$aTauopathies: drug therapy
000283145 650_2 $$2MeSH$$aMicroglia: metabolism
000283145 7001_ $$aSalomasova, Svetlana$$b1
000283145 7001_ $$aLalia, Manvir$$b2
000283145 7001_ $$0P:(DE-2719)9002311$$aKunze, Lea$$b3$$udzne
000283145 7001_ $$aPalumbo, Giovanna$$b4
000283145 7001_ $$aOos, Rosel$$b5
000283145 7001_ $$0P:(DE-2719)9003721$$aJoseph, Emanuel$$b6$$udzne
000283145 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b7$$eLast author$$udzne
000283145 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70856_104796$$gVol. 21, no. S2, p. e104796$$nS2$$pe104796$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283145 8564_ $$uhttps://pub.dzne.de/record/283145/files/DZNE-2026-00041.pdf$$yRestricted
000283145 8564_ $$uhttps://pub.dzne.de/record/283145/files/DZNE-2026-00041.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283145 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002311$$aExternal Institute$$b3$$kExtern
000283145 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003721$$aExternal Institute$$b6$$kExtern
000283145 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000283145 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000283145 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283145 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283145 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283145 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283145 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283145 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283145 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283145 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283145 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283145 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283145 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000283145 980__ $$aabstract
000283145 980__ $$aEDITORS
000283145 980__ $$aVDBINPRINT
000283145 980__ $$ajournal
000283145 980__ $$aI:(DE-2719)1110007
000283145 980__ $$aUNRESTRICTED